Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy

  • Technology appraisal guidance
  • TA329
  • Published: 

Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line) [ID695]: Evaluation report part1

Table of Contents

01. Overview prepared by NICE
02. Assessment Report
03. Comment on the Assessment Report
04. Comments on the executable model
05. Comment on the Assessment Report - British Society of Gastroentrology
06. Comments on the executable model - British Society of Gastroentrology
07. Comment on the Assessment Report CTHC
08. Comments on the executable model - Celltrion
09. Comments on the Assessment Report - HIR
10. Comments on the Assessment Report - MSD
11. Comments on the executable model - MSD
12. RCP response - endorsement
13. Comment on the Assessment Report - UKCPA
14. Response to comments on the Assessment Report prepared by School of Health Related Research
15. Manufacturer's submission - AbbVie

This page was last updated: 24 September 2014